JO3148B1 - مركب مثبط لإشارات مسار notch - Google Patents

مركب مثبط لإشارات مسار notch

Info

Publication number
JO3148B1
JO3148B1 JOP/2012/0190A JOP20120190A JO3148B1 JO 3148 B1 JO3148 B1 JO 3148B1 JO P20120190 A JOP20120190 A JO P20120190A JO 3148 B1 JO3148 B1 JO 3148B1
Authority
JO
Jordan
Prior art keywords
signaling inhibitor
notch pathway
pathway signaling
inhibitor compound
compound
Prior art date
Application number
JOP/2012/0190A
Other languages
English (en)
Inventor
Alan Stephenson Gregory
Arthur Hipskind Philip
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3148B1 publication Critical patent/JO3148B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يوفر الاختراع الحالي مركب، أو ملح أو هيدرات مقبولين صيدليًا، وتركيبة صيدلية تحتوي على المركب المذكور، أو ملح أو هيدرات مقبولين صيدليًا، ويكون مفيدًا كمثبِّط لإشارات مسار Notch لعلاج السرطان.
JOP/2012/0190A 2011-07-27 2012-07-10 مركب مثبط لإشارات مسار notch JO3148B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
JO3148B1 true JO3148B1 (ar) 2017-09-20

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0190A JO3148B1 (ar) 2011-07-27 2012-07-10 مركب مثبط لإشارات مسار notch

Country Status (36)

Country Link
US (1) US8569286B2 (ar)
EP (1) EP2736920B1 (ar)
JP (1) JP6027110B2 (ar)
KR (1) KR101578309B1 (ar)
CN (1) CN103732612B (ar)
AP (1) AP4080A (ar)
AR (1) AR087107A1 (ar)
AU (1) AU2012287251B2 (ar)
BR (1) BR112014001600B1 (ar)
CA (1) CA2841178C (ar)
CL (1) CL2014000175A1 (ar)
CO (1) CO6862159A2 (ar)
CR (1) CR20140036A (ar)
CY (1) CY1116645T1 (ar)
DK (1) DK2736920T3 (ar)
DO (1) DOP2014000011A (ar)
EA (1) EA023044B1 (ar)
EC (1) ECSP14013179A (ar)
ES (1) ES2544937T3 (ar)
GT (1) GT201400012A (ar)
HK (1) HK1194086A1 (ar)
HR (1) HRP20150771T1 (ar)
HU (1) HUE027534T2 (ar)
IL (1) IL229988A (ar)
JO (1) JO3148B1 (ar)
MA (1) MA35611B1 (ar)
ME (1) ME02171B (ar)
MX (1) MX356536B (ar)
MY (1) MY184303A (ar)
PE (1) PE20141061A1 (ar)
PL (1) PL2736920T3 (ar)
PT (1) PT2736920E (ar)
RS (1) RS54135B1 (ar)
SI (1) SI2736920T1 (ar)
TW (1) TWI568730B (ar)
WO (1) WO2013016081A1 (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
ES2898952T3 (es) * 2016-04-12 2022-03-09 Lilly Co Eli Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
US10688104B2 (en) * 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
JP2019526632A (ja) * 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
IL268349B1 (en) 2017-02-17 2024-04-01 Hutchinson Fred Cancer Res Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders
CA3082010A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019090364A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
CA3099479A1 (en) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
CA3114113A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions and methods related to otic therapeutic agents
WO2020210388A1 (en) 2019-04-08 2020-10-15 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069654A (ko) * 1996-12-23 2000-11-25 엘란 파마슈티칼스, 인크. 시클로알킬, 락탐, 락톤 및 관련 화합물, 그의 약제학적 조성물및 그를 사용한 β-아밀로이드 펩티드의 방출 및(또는) 합성억제 방법
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO1999067221A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
RU2330849C2 (ru) 2003-02-04 2008-08-10 Ф.Хоффманн-Ля Рош Аг МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ
JP4571639B2 (ja) 2003-09-09 2010-10-27 エフ.ホフマン−ラ ロシュ アーゲー ガンマ−セクレターゼの活性を阻害するマロンアミド誘導体
PL1673347T3 (pl) 2003-10-06 2016-01-29 Hoffmann La Roche Podstawione pochodne dibenzo-azepiny i benzo-diazepiny użyteczne jako inhibitory gamma-sekretazy
CA2645756C (en) 2006-03-27 2013-12-31 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
CN101622232A (zh) * 2007-02-02 2010-01-06 弗·哈夫曼-拉罗切有限公司 6-氧代-6,7-二氢-5h-二苯并[b,d]氮杂䓬-7-基衍生物
RU2010133489A (ru) 2008-01-11 2012-02-20 Ф.Хоффманн-Ля Рош Аг (Ch) Применение ингибиторов гамма-секретазы для лечения рака
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
DOP2014000011A (es) 2014-07-31
ME02171B (me) 2015-10-20
AP4080A (en) 2017-03-29
PE20141061A1 (es) 2014-09-06
KR20140026624A (ko) 2014-03-05
CO6862159A2 (es) 2014-02-10
HK1194086A1 (en) 2014-10-10
MY184303A (en) 2021-03-31
EA201490161A1 (ru) 2014-04-30
MX356536B (es) 2018-06-01
CN103732612B (zh) 2015-09-23
SI2736920T1 (sl) 2015-08-31
BR112014001600B1 (pt) 2022-09-13
CA2841178C (en) 2016-12-20
MA35611B1 (fr) 2014-11-01
AU2012287251B2 (en) 2015-05-14
JP6027110B2 (ja) 2016-11-16
KR101578309B1 (ko) 2015-12-16
DK2736920T3 (en) 2015-07-20
IL229988A (en) 2017-07-31
JP2014527042A (ja) 2014-10-09
RS54135B1 (en) 2015-12-31
HRP20150771T1 (hr) 2015-08-28
TW201315732A (zh) 2013-04-16
TWI568730B (zh) 2017-02-01
NZ618891A (en) 2015-12-24
CY1116645T1 (el) 2017-03-15
WO2013016081A1 (en) 2013-01-31
HUE027534T2 (en) 2016-11-28
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
EP2736920B1 (en) 2015-07-01
CN103732612A (zh) 2014-04-16
GT201400012A (es) 2014-07-16
BR112014001600A2 (pt) 2017-02-21
ES2544937T3 (es) 2015-09-07
US20130029972A1 (en) 2013-01-31
US8569286B2 (en) 2013-10-29
CL2014000175A1 (es) 2014-08-22
AU2012287251A1 (en) 2014-01-30
PL2736920T3 (pl) 2015-11-30
AR087107A1 (es) 2014-02-12
PT2736920E (pt) 2015-09-16
CR20140036A (es) 2014-03-21
AP2014007362A0 (en) 2014-01-31
EP2736920A1 (en) 2014-06-04
MX2014001084A (es) 2014-02-27
ECSP14013179A (es) 2014-03-31

Similar Documents

Publication Publication Date Title
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
IN2014DN10670A (ar)
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX362879B (es) Usos novedosos.
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch